The following slides were presented at the TIGA Workshop, and are enclosed in the PP show format (*.pps) in order to include all presented details.

Similar documents
Image analysis in IHC overview, considerations and applications

Next generation image analysis for immunohistochemistry quantitation

HER2 CISH pharmdx TM Kit Interpretation Guide Breast Cancer

HER2 FISH pharmdx TM Interpretation Guide - Breast Cancer

Use of tissue micro array (TMA) in routine clinical analysis

NordiQC External Quality Assurance in Immunohistochemistry

Abstract. Background. Objective

COMPUTER-AIDED HER-2/neu EVALUATION IN EXTERNAL QUALITY ASSURANCE (EQA) OF BREAST CANCER SCREENING PROGRAMME

Quality assurance and quality control in pathology in breast disease centers

Quantitative Image Analysis of HER2 Immunohistochemistry for Breast Cancer

Dr. dr. Primariadewi R, SpPA(K)

Product Introduction

Next-Gen Analytics in Digital Pathology

Breast cancer: Antibody selection, protocol optimzation controls and EQA

External Quality Assessment of Breast Marker Analysis. NordiQC data

NordiQC - update

Welcome! HER2 TESTING DIAGNOSTIC ACCURACY 4/11/2016

Three Hours Thirty Minutes

Supplementary Online Content

IT S ABOUT TIME. IQFISH pharmdx Interpretation Guide THREEHOURSTHIRTYMINUTES. HER2 IQFISH pharmdxtm. TOP2A IQFISH pharmdxtm

The unknown primary tumour: IHC classification part I, the primary panel - Antibody selection, protocol optimization, controls and EQA

Reviewer's report. Version: 1 Date: 24 May Reviewer: Cathy Moelans. Reviewer's report:

Visual interpretation in pathology

Instant Quality FISH. The name says it all.

HER2 ISH (BRISH or FISH)

Digital Pathology and CAP Guidelines

The unkown primary tumour: IHC Classification, antibody selection, protocol optimization, controls and EQA (part I)

DENOMINATOR: All melanoma pathology reports for primary malignant cutaneous melanoma

Quality Assurance and Quality Control in the Pathology Dept.

Technique and feasibility of a dual staining method for estrogen receptors and AgNORs

Prosigna BREAST CANCER PROGNOSTIC GENE SIGNATURE ASSAY

Prosigna BREAST CANCER PROGNOSTIC GENE SIGNATURE ASSAY

Breast Cancer Interpretation Guide

PROTOCOL SENTINEL NODE BIOPSY (NON OPERATIVE) BREAST CANCER - PATHOLOGY ASSESSMENT

Interpreting Therapeutic Response on Immune Cell Number and Spatial Distribution within the Tumor Microenvironment. Lorcan Sherry, CSO OracleBio

Combination of life science entrepreneurs, software development and machine vision experts & recognized scientists.

Quality Assurance in Immunohistochemistry: Experiences from NordiQC

Layered-IHC (L-IHC): A novel and robust approach to multiplexed immunohistochemistry So many markers and so little tissue

Deciphering the biology that drives response to immunotherapy

Assessment Run B HER-2

Assessment Run B HER-2 IHC. HER-2/chr17 ratio**

Assessment Run B HER2 IHC

MEDICAL POLICY. Proprietary Information of YourCare Health Plan

Assessment of Breast Cancer with Borderline HER2 Status Using MIP Microarray

Guideline. Associated Documents ASCO CAP 2018 GUIDELINES and SUPPLEMENTS -

Tissue microarray TMA

Immunohistochemical classification of the unknown primary tumour (UPT) Part I. Prof. Mogens Vyberg NordiQC Institute of Pathology Aalborg, Denmark

Does digital IHC need digital tissue controls?

MEDICAL POLICY. Proprietary Information of Excellus Health Plan, Inc. A nonprofit independent licensee of the BlueCross BlueShield Association

Assessment Run B HER2 IHC

Disruptive innovation in molecular diagnostics. Hilde Windels CEO Biocartis 25 March 2017

UCL-Advanced Diagnostics. 2015/16 Service Update

Removal of sentinel lymph node(s)

Immune Cell Phenotyping in Solid Tumors using Quantitative Pathology

Comparative Analysis of Methods Used in Breast Cancer HER2 and Sentinel Lymph Node Diagnosis

Workflow. Connecting the Pieces For Total Patient Care

Digital image analysis: a review of reproducibility, stability and basic requirements for optimal results

CC01 - Colon Cancer Tissue Microarray

College of American Pathologists. Pathology Performance Measures included in CMS 2012 PQRS

Case 26 Male 37. Right jawline 5mm nodule?keloid. The best diagnosis is:

Bioimaging and Functional Genomics

Conflict of Interest. Thank you. I have no relevant conflicts of interest in regards to the content of this presentation.

Automatic analysis of virtual slides to help in the determination of well established prognostic parameters in breast carcinomas

Digital Pathology Diagnosis Assistance System

Clinical utility of cancer biomarkers assessed by virtual microscopy

Classification of the unknown primary tumour: the primary IHC panel

Quality control of PD-L1 in NSCLC - Results of two German ring trials Dr. Andreas Scheel University Hospital Cologne

Case Scenario 1 History and Physical 3/15/13 Imaging Pathology

Evaluation of Breast Specimens Removed by Needle Localization Technique

Whitney A. High, MD, JD, MEng

Dako IT S ABOUT TIME. Interpretation Guide. Agilent Pathology Solutions. ALK, ROS1 and RET IQFISH probes (Dako Omnis) MET IQFISH probe (Dako Omnis)

Version 2 of these Guidelines were drafted in response to published updated ASCO/CAP HER2 test Guideline Recommendations-

Definiens. Tissue Studio 4.2. Tutorial 8: Cell Simulation and Classification

CANCER. Clinical Validation of Breast Cancer Predictive Markers

NIH Public Access Author Manuscript Cancer Epidemiol Biomarkers Prev. Author manuscript; available in PMC 2011 January 1.

Gaining New Insights Through IF Multiplexed Staining and Analysis. Tyna Hope, Ph.D. P.Eng Biomarker Imaging Research Laboratory October 5, 2017

PRODUCT INFORMATION. New Reagents for Dako CoverStainer. Choose the H&E staining intensity you want.

The High-End Solution for Real-Time Patient Tracking

Sentinel Node Biopsy in the Treatment of Oral Cancer. Patient Information Leaflet

Breast Unit - University of Heidelberg - Heidelberg, Germany

DIAGNOSTIC SLIDE SEMINAR: PART 1 RENAL TUMOUR BIOPSY CASES

(a) Significant biological processes (upper panel) and disease biomarkers (lower panel)

PD-L1 Analyte Control DR

Assessment performed on Friday, September 18, 2015, at Vancouver General Hospital

Supplementary Online Content

LN04 - Lymphoma Tissue Microarray

Anti-hTERT Antibody (SCD-A7)

Priti Lal, MD, 1 Paulo A. Salazar, 1 Clifford A. Hudis, MD, 2 Marc Ladanyi, MD, 1 and Beiyun Chen, MD, PhD 1. Abstract

Mamma Centrum / Zelený Pruh - Prague, Czech Republic

Determination of HER2 Amplification by In Situ Hybridization. When Should Chromosome 17 Also Be Determined?

Update: Morphologic Considerations in Mesothelioma within the Pleural and Peritoneal Cavities. Douglas J. Hartman, MD June 7, 2018

HSL-Advanced Diagnostics 2018 / 19 Test & Service List

A View to the Future: The Development of Targeted Therapy for Melanoma. Michael Davies, M.D., Ph.D.

Final Project Report Sean Fischer CS229 Introduction

Breast cancer diagnostic solutions Deliver diagnostic confidence

A712(19)- Test slide, Breast cancer tissues with corresponding normal tissues

Optimal algorithm for HER2 testing

Contemporary Classification of Breast Cancer

10 years of NordiQC Why are 30% of labs still getting it wrong?

NCDB Vendor Webinar: NCDB Call for Data January 2018 and Upcoming RQRS Revisions

Transcription:

Disclaimer: The following slides were presented at the TIGA Workshop, and are enclosed in the PP show format (*.pps) in order to include all presented details. These slides are proprietary and should not be copied or otherwise reproduced in part without the written permission from Visiopharm (contact Niels Foged, ntf@visiopharm.com)

1 st European Workshop on Tissue Imaging and Analysis Heidelberg Feb 13-14 2009 at Copenhagen University LIFE Quantitative Histomorphometry of Whole Slide Digital Images of Tumor Tissue Michael Grunkin & Niels T. Foged

Visiopharm A/S: A brief company introduction Founded in 2001. HQ in Copenhagen. Subsidiary in US Business focus: Automated quantitative microscopy Products: Advanced software for histomorphometry Customers: Scientists in universities/hospitals & biotech/pharma Increasing requests: Pathologists and teachers

Products: Software modules for automated: imaging, data base management, image analysis and stereology Software handles all types of image files. Visiopharm software users can easily switch between traditional microscopy and slide scanning. Visiopharm is expanding from life science to clinical applications

Collaboration projects in (breast) cancer pathology Malignancy grading H&E Primary Tumor IHC Proximity ligation IHC Tubularity Nucl. pleomorph. Mitotic grade ER/PR IHC HER-2 IHC TIMP-1 IHC

Proximity Ligation Assay (PLA) Dual antibody-based immunohistochemistry, e.g. HER-2/3 dimers Blob -signals by Rolling Circle Amplification Quantification of signals per cell by Visiomorph TM software module Assay kits by Olink AB; Uppsala, Sweden

Collaboration projects in (breast) cancer pathology Malignancy grading H&E Primary Tumor IHC Proximity ligation IHC Sentinel node IHC Chromosomal FISH/CISH Tubularity Nucl. Pleomorph. Mitotic grade HER2 FISH/CISH TOP2A FISH/CISH TIMP-1 FISH/CISH ER/PR IHC HER-2 IHC TIMP-1 IHC Individual grading and staging of cancer SLN metastasis: Presence Vol./stereology Today s focus: HER-2 Immunohistochemistry

HER-2 IHC Algorithm: Work in progress Clinical collaboration study with Mogens Vyberg, NordiQC (Aalborg Hospital) Tumor tissue from 75 breast cancer patients Three TMA s stained with the Herceptest TM (Dako) Adjudicated consensus scores by a panel of expert pathologists Scanned with Nanozoomer @ x20 Visiopharm proprietary software used for feature extraction

ENHANCING STAINED NUCLEI (BLUE) USING A SPECIAL FILTER

ENHANCING STAINED MEMBRANES (BROWN) USING A SPECIAL FILTER

POST PROCESSING STEP1: Remove (too) small nuclei & membrane objects

POST PROCESSING STEP2: Remove nuclei without a membrane and membrane structures without a nucleus

FINAL SEGMENTATION

MEASURING STAINING INTENSITY Using a special algorithm quantifying brown

MEASURING STAINING INTENSITY Measuring average staining intensity (i.e. brown) below the identified membrane label

PLANIMETRIC FEATURES Measuring area of membrane, number of nuclei, and average amount of membrane per identified nucleus.

Preliminary results of comparison to consensus scores obtained by manual microscopy 7,5 HercepTest (Dako) 7 6,5 Score by Visiopharm image analysis algorithm 6 5,5 5 4,5 n=71 (work-inprogress) 4 3,5-1 0 1 2 3 Consensus score by Manual Microscopy

Please feel free to visit the Visiopharm booth for further discussions and a live demo by Jakob Raundahl, PhD